Chiral Organophosphorus Pharmaceuticals: Properties and Application

Author:

Kolodiazhna Anastasy O.1,Kolodiazhnyi Oleg I.1ORCID

Affiliation:

1. V.P. Kukhar’ Institute of Bioorganic Chemistry and Petrochemistry, National Academy of Sciences of Ukraine, Kukharia Academika St., 1, 02094 Kyiv, Ukraine

Abstract

This review considers the chiral phosphorus-containing drugs used to treat patients in the clinic, as well as the promising and experimental drugs that are in the process of being researched. Natural and synthetic representatives of phosphorus-containing drugs, such as tenofovir (hepatitis B and HIV treatment), fosfomycin (antibiotic), valinofos (antibiotic), phosphazinomycin A (antibiotic), (R)-phospholeucine, various antibacterial and antifungal agents, renin inhibitors, etc., have found practical applications as medicines and bioregulators and other medicines. The influence of the chirality of both carbon atoms and phosphorus atoms on the pharmacodynamics, pharmacokinetics, and toxicological properties of phosphorus drugs has been demonstrated. Therefore, the choice of enantiomers is critical since the wrong choice of a chiral drug can lead to undesirable consequences, carcinogenicity, and teratogenicity. New chiral technologies affecting drug development are discussed, such as the “chiral switch” of racemates already on the market, as well as phosphorus-containing prodrugs with a higher biological selectivity and low adverse effects.

Publisher

MDPI AG

Subject

Physics and Astronomy (miscellaneous),General Mathematics,Chemistry (miscellaneous),Computer Science (miscellaneous)

Reference125 articles.

1. Food and Drug Administration (2010, April 23). Development of New Stereoisomeric Drugs. 6 July 2005, Available online: www.fda.gov/Drugs/GuidanceComplianceRegulatorylnformation/Guidances/ucm122883.htm.

2. Stereochemistry: Definitions and a note on nomenclature;Caldwell;Hum. Psychopharmacol.,2001

3. Reddy, I., and Mehvar, R. (2004). Regulatory Considerations in Drug Development of Stereoisomers, Chiralitv in Drug Design and Development, CRC Press.

4. Agency, E.M. (2010, April 25). Investigation of Chiral Active Substances; 1994. Available online: www.ema.europa.eu/pdfs/human/qwp/3cc29aeu.pdf.

5. Putting chirality to work: The strategy of chiral switches;Agranat;Nat. Rev. Drug Discov.,2002

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3